<DOC>
	<DOCNO>NCT02575040</DOCNO>
	<brief_summary>The gut microbiota determine constitute `` microbial organ '' pivotal role intestinal disease body 's metabolism . Evidence animal human study strongly support link intestinal bacteria flora inflammatory bowel disease . Lots study show efficacy treatment severe Clostridium difficile colitis . Corticosteroid dependence patient ulcerative colitis ( UC ) Crohn 's disease ( CD ) important clinical problem maintenance steroid-free remission key treatment goal . Early study use fecal microbiota transplantation ( FMT ) Ulcerative Colitis ( UC ) Crohn 's disease also meet success . This first step investigate potential efficacy standardize FMT terminal ileum UC CD , investigator propose determine efficiency safety FMT series 80 patient moderate severe UC CD .</brief_summary>
	<brief_title>Efficacy Fecal Microbiota Transplantation Inflammatory Bowel Disease</brief_title>
	<detailed_description>Intestinal microbiota major role disease pathogenesis , either form `` permissive '' role direct pathogenic cause . Clostridium difficile colitis ; irritable bowel syndrome ( IBS ) inflammatory bowel disease ( IBD ) connect disturbance equilibrium intestinal microbiome . The cause IBD unknown evidence get immense immune reaction intestinal immune system microflora combine genetic predisposition responsible chronic inflammation . Fecal microbial treatment ( FMT ) treatment utilizes microbiota healthy intestine probiotic preparation . The fecal material healthy individual fluidized inserted intestinal tract sick individual , assume healthy flora colonize cure intestine . Previous work show success fecal transplantation treatment clostridium difficile colitis . There also report efficacy treatment inflammatory bowel disease currently number small . 41 case report , In FMT insert nasogastric tube directly duodenum , colonoscopy enema . A significant clinical improvement report 19 25 patient . 13 17 stop IBD treatment , 15 24 enter full clinical remission . In 15 patient treated infection treatment successful . No sever adverse effect report , Fever develop 8 case one case exacerbation colitis treatment . Primary aim : To investigate whether use FMT bring improvement least 2 point partial mayo score ulcerative colitis patient , 75 point CDAI patient Crohn 's colitis . One month FMT . Improvement define : For Ulcerative colitis : decrease least 2 point partial mayo score , decrease least 1 point endoscopic Mayo score . For Crohn 's disease : A decrease least 70 point Crohn 's disease activity index ( CDAI ) . 80 patient age &gt; 18 year , histological endoscopic diagnosis ulcerative colitis ( UC ) CD respond either thiopurines tumor necrosis factor ( TNF ) inhibitor . Flare define partial mayo score high 3 , either C reactive protein ( CRP ) high 6 endoscopic mayo score &gt; 1 ulcerative colitis CDAI high 220 CRP high 6 Crohn 's colitis . Stool donate patient choice either relative , preferably partner minimize possible transference infective agent , alternatively sample order `` open biom '' .</detailed_description>
	<mesh_term>Colitis , Ulcerative</mesh_term>
	<mesh_term>Constipation</mesh_term>
	<mesh_term>Crohn Disease</mesh_term>
	<mesh_term>Intestinal Diseases</mesh_term>
	<mesh_term>Inflammatory Bowel Diseases</mesh_term>
	<mesh_term>Fecal Impaction</mesh_term>
	<criteria>Signed informed consent Inflammatory bowel disease diagnose least 6 month ago Failure either one immunomodulator least 3 month duration , TNF inhibitor full induction treatment , corticosteroid , intolerance either drug . Currently active disease , partial Mayo score ≥4 ulcerative colitis , CDAI ≥200 CD . negative HIV , Human Tcell leukemia virus I/II , negative stool culture , Negative C diff toxin , negative Cytomegalovirus No inform consent Non active inflammatory bowel disease . Active infection either donor recipient , Response biological agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>